PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28972699-3	2018	Ledipasvir along with Sofosbuvir has been approved for management of genotype 1 infection in patients with eGFR >=30 mL/min.	Sofosbuvir	22-32	epidermal growth factor receptor	Homo sapiens	107-111	
32316635-0	2020	Sofosbuvir Activates EGFR-Dependent Pathways in Hepatoma Cells with Implications for Liver-Related Pathological Processes.	Sofosbuvir	0-10	epidermal growth factor receptor	Homo sapiens	21-25	
32316635-4	2020	We found that treatment with sofosbuvir (SOF), a backbone of DAA therapy, caused an increase in EGFR expression and phosphorylation.	Sofosbuvir	29-39	epidermal growth factor receptor	Homo sapiens	96-100	
32316635-4	2020	We found that treatment with sofosbuvir (SOF), a backbone of DAA therapy, caused an increase in EGFR expression and phosphorylation.	Sofosbuvir	41-44	epidermal growth factor receptor	Homo sapiens	96-100	
32816249-10	2020	Age > 65 years, baseline eGFR, and ribavirin-containing regimens were independent risk factors of eGFR decline during and after SOF-based treatment.	Sofosbuvir	128-131	epidermal growth factor receptor	Homo sapiens	98-102